Technology has been one of the most powerful wealth-creating sectors of the past two decades, and there's every reason to think the trend will continue.
From cloud computing and artificial intelligence to digital commerce and software as a service, the companies powering these themes are seeing their markets expand at a rapid clip.
For investors looking to capture that growth, the ASX is home to several world-class tech shares that analysts are tipping as buys. Here's what they are recommending:
WiseTech Global Ltd (ASX: WTC)
WiseTech could be a top ASX tech share to buy and hold. Its logistics software is used by some of the largest freight forwarders and transport companies on the planet.
Its flagship CargoWise platform has become deeply embedded in the global supply chain, making it incredibly difficult for customers to switch away. And with international trade volumes growing and supply chains becoming ever more complex, WiseTech is in a strong position to grow over the next decade and beyond.
Morgans is positive on the company and sees plenty of upside for investors. It has a buy rating and $127.60 price target on its shares.
NextDC Ltd (ASX: NXT)
Another ASX tech share that could be a top long term option is data centre operator NextDC.
The world's insatiable appetite for data is creating enormous opportunities for data centre operators. Especially NextDC and its world class facilities, which are critical infrastructure for cloud computing, artificial intelligence, and digital services.
And with demand for capacity continuing to accelerate, the company unsurprisingly announced record contracted sales recently and revealed plans to expand its footprint across Australia and Asia.
For investors who believe in the ongoing digitisation of the global economy, NextDC looks like one of the best positioned ASX tech shares.
Morgan Stanley is very bullish on the company's outlook. This morning, its analysts put an overweight rating and $20.50 price target on its shares.
Pro Medicus Ltd (ASX: PME)
Finally, Pro Medicus has become a genuine global healthcare technology leader thanks to its advanced medical imaging software.
Its flagship Visage platform allows doctors and hospitals to process and interpret massive imaging files with remarkable speed and clarity, improving patient outcomes and workflow efficiency. This is particularly important at this time given the shortage of radiologists.
With multi-year contracts locked in with leading US hospitals and growing adoption across Europe and Australia, Pro Medicus enjoys powerful recurring revenues and one of the strongest margins on the ASX.
Morgan Stanley is also tipping Pro Medicus as an ASX tech share to buy. It has an overweight rating and $350.00 price target on its shares.
